Objectives: Elderly endometrial cancer patients have worse disease-specific survival than their younger counterparts, but the cause for this discrepancy is unknown. The goal of this analysis is to compare outcomes by age in a fully staged elderly endometrial cancer population. Methods/Materials: This is an analysis of patients on Gynecologic Oncology Group Study (GOG) LAP2, which included clinically early stage endometrial cancer patients randomized to laparotomy versus laparoscopy for surgical staging. Patients were divided into risk groups based on criteria defined by GOG protocol 99. Differences in outcomes and adjuvant therapy were assessed within these risk groups. Results: LAP2 included 715 patients 70 years or older. With increasing age, worse tumor characteristics were seen. Older patients received similar rates of adjuvant therapy when stratified by stage. Patients 70 years or older had significantly worse progression-free survival and overall survival, and on multivariate analysis, older age and high-risk uterine factors were predictors of progression-free survival and overall survival, whereas stage and lymph node metastases were not. When patients were divided into GOG protocol 99 risk categories, most of those who met the high-intermediate risk criteria did so based on age above 70 years and grade 2 to 3 disease. These patients had low risk of recurrence (3.3%) compared with those who met the criteria by age above 70 years and all 3 uterine factors (20.9%).
ndometrial cancer, a disease that generally occurs in postmenopausal women, is expected to increase in prevalence as the population ages. In 2015, there were over 52,000 new cases of endometrial cancer diagnosed in the United States with over 8500 deaths. Although only 25% of cases are diagnosed in women older than 75 years, 50% of deaths due to endometrial cancer occur in these patients. 1, 2 Potential factors that cause this difference in incidence and mortality include more aggressive tumors in elderly women, less aggressive therapy for elderly patients, and age, which is a poor prognostic marker for endometrial cancer.
Previous studies show that age plays a role in predicting recurrence in endometrial cancer. Gynecologic Oncology Group Study (GOG)-99 was designed to compare surgery alone (total abdominal hysterectomy, bilateral salpingooophorectomy including lymphadenectomy) versus surgery and adjuvant radiotherapy in patients with stages IB, IC, and occult stage II endometrioid endometrial cancer. There was a significant decrease in recurrence rates (12% vs 3%) in patients treated with postoperative radiotherapy but no difference in overall survival (OS). A subset analysis identified a group with a 25% risk of recurrence. This high-intermediate risk (H-IR) group is identified by age and uterine risk factors, including grade 2 or 3, presence of lymphovascular space invasion (LVSI), and depth of invasion to the outer one third of the myometrium. The GOG protocol 99 (GOG-99) algorithm identified H-IR patients as older than 70 years + 1 uterine factor, 50 to 70 years + 2 factors, or any age + 3 factors. 3 Other studies such as the first Postoperative Radiotherapy in Endometrial Cancer trial also found that age was associated with increased disease recurrence. 4 In 1996, the GOG started a randomized prospective trial (GOG-2222 or LAP2) to compare comprehensive surgical staging by laparotomy versus laparoscopy for the treatment of clinical stage I to IIA uterine cancer (n = 2616). The GOG has published results of LAP2 regarding surgical outcomes, completeness of surgical staging, recurrence-free survival, and quality of life. 5, 6 LAP2 is one of the largest prospective trials looking at outcomes in clinically early stage endometrial cancer and has 715 patients 70 years or older. This allows for a retrospective assessment of a large subset of elderly patients with clinically early stage endometrial cancer.
The goal of this ancillary review is to report the surgicopathologic findings, recurrence, and survival outcomes in patients 70 years or older versus patients younger than 70 years who participated in GOG LAP2. The results of this study will further elucidate the etiologies of the discrepancies seen in incident cases of, and mortality due to, endometrial cancer in elderly patients. Gynecologic Oncology Group Study LAP2 included patients with primarily early stage disease and good performance status and required complete surgical staging, so differences in outcomes should be attributable to disease and postoperative therapy.
MATERIALS AND METHODS
This is an analysis of patients enrolled on GOG LAP2. The details of inclusion and exclusion criteria can be seen in the original manuscript. 5 The study was designed to compare laparoscopy with laparotomy for the purpose of complete comprehensive surgical staging of uterine cancer. The primary outcome of the study was recurrence-free survival. Other end points included perioperative adverse events, quality of life, and survival. Eligibility requirements were clinical stage I to IIA uterine cancer, adequate bone marrow, renal and hepatic function, and GOG performance status less than 4.
The initial analysis in this retrospective study involved comparing adjuvant therapy and outcomes by age in the entire LAP2 population. Subsequently, patients were divided into risk groups defined by GOG-99 based on pathologic findings. The GOG-99 H-IR group included stage I and occult stage II patients with endometrioid histology who met the criteria listed in the introduction. To reflect updated staging from 2009, depth of invasion greater than 50% was used, whereas in GOG-99, H-IR was defined as outer third invasion. In patients older than 70 years, the recurrence rates were compared between patients who met the H-IR criteria by age and additional uterine risk factors. Differences in outcomes and adjuvant therapy were assessed within these risk groups. Categorical variables were compared between the subgroups by using the Pearson W 2 test and continuous variables by using the Wilcoxon-MannWhitney test or the Kruskal-Wallis test.
7Y9 Survival was estimated using the Kaplan-Meier method. 10 The Cox proportional hazards model was used to evaluate independent prognostic factors (including age, race/ethnicity, body mass index [BMI] , International Federation of Gynecology and Obstetrics [FIGO] stage, tumor grade, performance status, lymphovascular invasion, and nodal metastasis), without any variable selection, and to estimate their covariate-adjusted effects on survival. 11 The nonlinearity of the effect of continuous variables was assessed using restricted cubic splines, 12 and multicollinearity was checked through the method of variance inflation factors. 13 All statistical tests were 2 tailed with a significance level set at > = 0.05. Statistical analyses were performed using R programming language and environment. 14 
RESULTS

Total LAP2 Population Uterine Characteristics and Adjuvant Treatment
A total of 2516 patients were included in this analysis based on LAP2 eligibility. When the total LAP2 population was divided into age by decade, 555 patients (21.2%) were aged 70 to 79 years and 160 patients (6.4%) were 80 years or older. With increasing age, there were increased rates of serous histology (P G 0.001), stage 1B versus stage 1A (FIGO 2009 staging 15 ) and overall higher stage disease (P G 0.001), grade 3 tumors (P G 0.001), and positive LVSI (P G 0.001) ( Table 1) . Most of the patients on LAP2 had endometrioid or serous histology, so only these histologies are shown, but all histological subtypes were included in the analysis. When comparing postoperative therapy, the rates of chemotherapy were similar across the age groups, ranging between 8.8% and 13.5% (P = 0.122), whereas the rates of radiation increased with increasing age until the age of 79 years, ranging from 20% in patients younger than 50 years to 30.6% in patients aged 70 to 79 years, at which point a drop in the percentage of patients 80 years or older treated with adjuvant radiation was seen (23.8%, P = 0.001). The rates of receiving any adjuvant therapy increased with increasing age until the age of 79 years, ranging from 22.8% in patients younger than 50 years to 36.9% in patients aged 70 to 79 years, at which point a drop in the percentage of patients 80 years or older receiving any adjuvant therapy was seen (29.4%, P G 0.001) ( Table 1) . However, when looking at the rates of adjuvant therapy by age and stage, there does not seem to be a clear tendency toward older patients receiving more or less adjuvant therapy (Table 1 and Supplementary Table 1 , Supplemental Digital Content, http://links.lww.com/IGC/A451); this is confirmed by an application of the Woolf test for an interaction to the age versus therapy contingency tables stratified by stage (P = 0.800, nonsignificant), followed by the Cochran-MantelHaenszel test for conditional independence (P = 0.232, nonsignificant).
Recurrence and Survival in Total LAP2 Population
In univariate analysis, the recurrence rates increased significantly with age, with 4.9% of patients younger than 50 years recurring compared with 14.4% of patients 80 years or older (P G 0.001). When looking at the cause of death, 1.5% of patients younger than 50 years died of disease compared with 16.5% of patients 80 years or older. Patients 80 years or older also died more often of causes unrelated to disease than patients younger than 50 years (23.4% vs 1.1%, P G 0.001) ( Table 1 ).
The 70-month progression-free survival (PFS) for patients younger than 70 years versus patients 70 years or older is 85% versus 65% (P G 0.001), respectively. The 70-month OS for patients younger than 70 years versus patients 70 years or older is 89% versus 69% (P G 0.001), respectively ( Fig. 1) .
On multivariate analysis, the factors significant for PFS were depth of invasion 50% or greater (hazard ratio [HR], 2.90; 95% confidence interval [CI], 1.46Y5.74; P = 0.002), grade 3 disease (HR, 2.14; 95% CI, 1.37Y3.34; P G 0.001), serous histology (HR, 1.59; 95% CI, 1.17Y2.16; P = 0.003), presence of LVSI (HR, 1.41; 95% CI, 1.11Y1.81; P = 0.005), and age (HR, 1.04; 95% CI, 1.03Y1.05; P G 0.001). For OS, these same factors remained significant with the addition of nonwhite race (HR, 1.55; 95% CI, 1.12Y2.14; P = 0.008) and BMI (HR, 1.02; 95% CI, 1.00Y1.04; P = 0.025). Stage, lymph node metastasis, performance status, and receiving postoperative therapy were not independent predictors for PFS or OS.
The GOG-99 H-IR Population Adjuvant Treatment
When patients were divided into risk groups based on the GOG-99 H-IR criteria, 37% (926) of the total LAP2 population met the GOG-99 H-IR criteria; 43% of these patients were 70 years or older. Although only 28% of the LAP2 population was 70 years or older, 55% met the GOG-99 H-IR criteria. Of the 926 H-IR patients, data about adjuvant therapy existed for 96% (892). A total of 28% received adjuvant treatment: 96% radiation, 5.2% chemotherapy and radiation, and 4% chemotherapy alone. When looking at the rates of adjuvant treatment across the age groups in this H-IR subset, as age increased, significantly less radiation was received with 60% of patients younger than 50 years receiving radiation versus 24% to 27% of patients 50 to 79 years and only 17.3% of patients 80 years or older (P = 0.011) ( Table 2 ). There is also a trend toward less treatment in older patients, but when the 15 patients younger than 50 years are excluded, similar rates of nonadjuvant therapy are seen across the remaining age groups with a range of 68.5% to 71.6%.
Recurrence and Survival in the GOG-99 H-IR Population
There are similar rates of disease recurrence across the age groups, ranging from 4.3% to 20% (P G 0.128), but older patients have higher death rates (P G 0.001). The main discrepancy in the cause of death between the age groups is causes unrelated to disease or treatment, with 3.4% of patients 60 to 69 years dying of causes unrelated to disease versus 13.9% of patients 80 years or older. Death from disease is generally low, ranging from 3.1% to 7.6% (Table 2) .
When looking at the recurrence rates in the entire GOG-99 H-IR group, the recurrence rates were significantly higher in the H-IR patients who received adjuvant therapy compared with the H-IR patients who received no adjuvant therapy (9.6% vs 4.4%, P = 0.003) with no significant difference in death rates between these groups (P = 0.20) (Table 3 ). Multivariate analysis of GOG-99 H-IR patients in LAP2 shows no difference in PFS and OS between treated versus untreated patients (P values, 0.83 and 0.80, respectively).
On multivariate analysis of the GOG-99 H-IR patients, the factors significant for PFS were 50% or greater depth of invasion (HR, 8.01; 95% CI, 1.48Y44.16; P = 0.017), grade 3 disease (HR, 1.99; 95% CI, 1.14Y3.49; P = 0.016), nonwhite race (HR, 1.62; 95% CI, 1.02Y2.89; P = 0.043), age (HR, 1.05; 95% CI, 1.03Y1.07; P G 0.001), and BMI (HR, 1.03; 95% CI, 1.01Y1.05; P = 0.008). For OS, these same factors remained significant except that depth of invasion lost significance and presence of LVSI (HR, 1.93; 95% CI, 1.19Y3.15; P = 0.008) was added. Meeting the GOG-99 H-IR criteria, stage, and receiving adjuvant therapy did not independently predict PFS or OS. The exclusion of advanced stage and high-risk histologies likely accounts for the overall low rate of disease recurrence in this subset, with 5.4% recurrence in patients aged 70 to 79 years 
Recurrence by Number of H-IR Risk Factors in the GOG-99 H-IR Population Older Than 70 Years
To further explore the contribution of age on risk for recurrence, patients older than 70 years were divided into those who met the GOG-99 H-IR criteria by age above 70 years and 1 other uterine factor and those who met the GOG-99 H-IR criteria by age above 70 years and 2 or 3 uterine factors (ie, this group met the H-IR criteria even if they were 50Y70 years old). Of the 361 patients older than 70 years who met the GOG-99 H-IR criteria, most (59%) met the criteria by age and grade 2 or 3 disease. The recurrence rate in this group was 3.3% (7/213). All other groups who met the GOG-99 H-IR criteria by age above 70 years and 1 uterine factor had a 0% recurrence rate, although numbers are low. Patients who met the H-IR criteria by age above 70 years and 2 uterine factors had a risk of recurrence of 0% to 7.6% with the highest in patients with grade 2 or 3 disease, 50% or greater depth of invasion, and negative LVSI. Finally, patients older than 70 years with all 3 uterine risk factors (n = 43) had the highest risk of disease recurrence at 20.9% (Table 4) .
DISCUSSION
Results from this analysis show that in a healthy, clinically early stage, fully staged endometrial cancer population, FIGURE 1. Kaplan-Meier estimates of (A) PFS and (B) OS for patients younger than 70 years and patients 70 years or older in the total LAP2 population. The 70-month PFS for patients younger than 70 years versus patients 70 years or older is 85% versus 65% (P G 0.001), respectively. The 70-month OS for patients younger than 70 years versus patients 70 years or older is 89% versus 69% (P G 0.001), respectively. The P values are for the log-rank tests comparing the pairs of survival curves. *Variables were compared between the patient subgroups by using the Pearson W 2 test. †The P value is from the log-rank test of survival differences among the age subgroups. patients 70 years or older have worse PFS and OS than patients younger than 70 years despite the same surgical management and similar rates of adjuvant therapy.
Retrospective studies have investigated the reason for worse outcomes in older endometrial cancer patients. A surveillance, epidemiology, and end results program retrospective analysis of over 37,000 women with endometrial cancer evaluated differences in surgical management and adjuvant therapy and found that 95% of women younger than 70 years underwent a hysterectomy, whereas only two thirds of patients older than 80 years did. For women aged 65 to 69 years, 43% underwent lymph node dissection, and only 25% of women older than 85 years did. Patients older than 70 years had higher grade and stage disease. This analysis found that older women were less likely to receive adjuvant radiation therapy. Cancer-specific mortality increased with age, with women 80 years or older more likely to die of endometrial cancer than women aged 65 to 69 years. This analysis suggests that worse disease-free survival seen in elderly patients is attributable to less aggressive primary and adjuvant therapies compared with younger patients. 16 Importantly, this study involves a different patient population than the current study.
Our results suggest that age and high-risk uterine factors account for worse survival in older endometrial cancer patients. Patients older than 70 years had higher rates of serous histology, high-grade disease, greater depth of invasion, and LVSI. These uterine factors, along with age, are associated with worse survival in multivariate analysis. Previous studies have found that serous carcinoma is associated with poor prognosis and occurs more frequently in older patients. Although only 10% of all endometrial cancers are serous histology, it accounts for 39% of endometrial cancer deaths. 17 Studies show that up to 22% of endometrial cancers diagnosed in women older than 75 years are serous cancers compared with only 3% in women younger than 45 years. 18 In this study, 20% of patients aged 70 to 79 years had serous histology compared with only 3% of patients younger than 50 years.
Although older patients in this study had higher rates of lymph node metastasis, this was not an independent predictor for PFS or OS. We have shown this in a previous study where 352 clinical stage 1 endometrial cancer patients were divided into GOG-99 and the first Postoperative Radiation therapy in Endometrial Cancer H-IR criteria, and uterine factors for recurrence, lymph node metastasis, and recurrence rates were compared. When uterine factors and lymph node status were both examined for the ability to predict recurrence, uterine factors were more important than nodal status. 19 In a retrospective chart review of patients with pelvic lymphadenectomy (an average of 6 lymph nodes removed) and paraaortic lymphadenectomy (12% of patients), the factors independently associated with increased risk of death included high-risk uterine factors but not pelvic node status when uterine factors were taken into account. 20 In the LAP2 study, the median pelvic and paraaortic lymph node count was 18 and 7 in the laparotomy group and 17 and 7 in the laparoscopy group. When looking at the GOG-99 H-IR group, a truly early stage, node-negative population with endometrioid histology, older patients received similar treatment and had similar, and low, recurrence rates compared with younger patients who met the same H-IR criteria, the only exception being patients younger than 50 years (n = 15) who had higher rates of adjuvant therapy compared with other ages. Older patients had worse survival, but the cause of death was mainly causes unrelated to disease. Receiving adjuvant treatment did not significantly change PFS or OS, and in fact, H-IR patients who received adjuvant treatment had higher rates of disease recurrence than H-IR patients who did not receive adjuvant therapy. The number of patients who recurred in these groups was overall low (28 recurrences in the H-IR group without adjuvant therapy vs 24 recurrences in the H-IR group with adjuvant therapy), limiting conclusions that can be drawn from these data. The site of recurrence was similar between these groups as well. On multivariate analysis of the GOG-99 H-IR population, age and uterine factors such as tumor grade and positive LVSI were predictors for survival. Details about medical comorbidities and toxicity from therapy, which are often more common in older patients, were not included in this analysis. This is a weak point of this study and could affect PFS and mortality from other causes and from disease.
As expected, with the exclusion of serous histology and occult advanced disease, the recurrence rates were lower in patients aged 70 to 79 years who met the GOG-99 H-IR criteria than in the same age group in the total LAP2 population (5.4% vs 14.6%). The GOG-99 H-IR group from this study had lower than expected recurrence rates compared with the GOG-99 results where the H-IR patients who received no adjuvant therapy had recurrence rates of 26% compared with 4.4% in the same population in this study, bringing to question the true impact age has on risk of recurrence. 3 Although multivariate analysis shows that age is an independent predictor for survival, our results also show that patients older than 70 years most commonly meet the GOG-99 H-IR criteria by only 1 uterine risk factor (grade 2 or 3 disease, Q50% depth of invasion, or presence of LVSI) and are actually at very low risk (0%Y3.3%) for recurrence compared with those older than 70 years with multiple risk factors where risk of recurrence is as high as 21%, which is helpful for guiding clinical decision-making.
Conclusions that can be drawn from looking at the risk models in this population are that older patients who are truly early stage, with endometrioid histology (GOG-99), are low risk even if they meet the H-IR criteria for recurrence and may be too low risk to benefit from adjuvant therapy. In this study, patients with occult stage 3 and 4 disease, as well as serous histology, likely account for most of the recurrences, making this the group who actually might benefit from adjuvant therapy, although standard of care is controversial.
It is also important to note that in all subsets analyzed, as age increased, patients more frequently died of causes unrelated to disease or treatment. Life expectancy for women at birth in the United States is 80.8 years, but once a woman reaches 70 years old, life expectancy increases with an expected 16 more years of life. 21 Frequently, endometrial cancer patients have multiple medical comorbidities that result in shorter life expectancy. Learning how to better assess comorbidities and their effect on life expectancy could allow physicians to tailor therapy more effectively. 
